Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-135 · 3 trials · 4 indications
The safety and tolerability as assessed by evaluating adverse events and laboratory testing.
| Arm | Type | Description |
|---|---|---|
| VX-135 low dose in combination with ribavirin | EXPERIMENTAL | 12 weeks of VX-135 in combination with ribavirin |
| VX-135 high dose in combination with ribavirin | EXPERIMENTAL | - |
| VX-135 High Dose with Daclatasvir | EXPERIMENTAL | 12 weeks of a high dose of VX-135 in combination with Daclatasvir |
| VX-135 Low Dose with Daclatasvir | EXPERIMENTAL | 12 weeks of a low dose of VX-135 in combination with Daclatasvir |
| VX-135 High Dose with ribavirin | EXPERIMENTAL | 12 weeks of a high dose of VX-135 in combination with ribavirin |
| VX-135 Low Dose with ribavirin | EXPERIMENTAL | 12 weeks of a low dose of VX-135 in combination with ribavirin |
| Name | Type | Description |
|---|---|---|
| VX-135 | DRUG | 12 weeks of VX-135 |
| Ribavirin | DRUG | 12 weeks of ribavirin |
| Daclatasvir | DRUG | - |
Key Inclusion Criteria: * Subjects (male and female) must be between 18-60 years of age * Subjects must have Chronic Hepatitis C * Subjects must be treatment naive * Subjects must have laboratory values at screening within limits as specified by the protocol Key Exclusion Criteria: * Evidence of ...
VX-135 is an investigational small molecule being developed for the treatment of chronic hepatitis C, a viral infection of the liver. It has been studied in Phase 2 clinical trials in patients with chronic hepatitis C, including those with genotype 1 infection.
VX-135 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company has conducted multiple clinical trials of VX-135 in patients with chronic hepatitis C.
VX-135 is in Phase 2 clinical development. It has completed three Phase 2 clinical trials, which were randomized, double-blind, and controlled. The drug is investigational and has not been approved by regulatory authorities.
VX-135 has been studied in three completed Phase 2 clinical trials. These include NCT01726946, a study of VX-135 with ribavirin in treatment-naive patients; NCT01790100, a dose-ranging study with ribavirin; and NCT01842451, a study of VX-135 with daclatasvir in genotype 1 chronic hepatitis C.
VX-135 is a small molecule drug that targets the hepatitis C virus. It is designed to interfere with viral replication, helping to clear the infection from the body. The drug has been studied in combination with other antiviral agents such as ribavirin and daclatasvir.